AMA GMO-Labeling Statement

Posted on

AMA policy supports the FDA's science-based approach to special product labeling, recognizing that there currently is no evidence that there are material differences or safety concerns in available bioengineered foods. Recognizing the public’s interest in the safety of bioengineered foods, the new policy also supports mandatory FDA pre-market systemic safety assessments of these foods as a preventive measure to ensure the health of the public. We also urge the FDA to remain alert to new data on the health consequences of bioengineered foods.

AMA board member Patrice Harris, M.D.